Recurrent IgA nephropathy after kidney transplantation remains a major cause of graft dysfunction. This case highlights successful management with targeted‐release budesonide combined with sparsentan, underscoring the importance of early recognition and the promise of emerging therapies to preserve long‐term allograft function.
Amyloid deposition is an increasingly recognized contributor to chronic kidney disease and end‐stage renal disease. It can result from various underlying conditions, including monoclonal gammopathies and chronic inflammatory states. Diagnosis is typically established by kidney biopsy demonstrating characteristic amyloid deposits. ALECT2 (leukocyte chemotactic factor 2) amyloidosis can present as nephrotic‐range proteinuria. ALECT2 amyloidosis is an uncommon and under‐recognized.
Thin basement membrane nephropathy is traditionally characterized by persistent microscopic hematuria and minimal proteinuria, and has long been considered a benign condition. However, emerging evidence challenges this view, as thin basement membrane nephropathy can occasionally present with nephrotic-range proteinuria. We report a case of a 53-year-old female with isolated nephrotic-range proteinuria, ultimately diagnosed with thin basement membrane nephropathy based on electron microscopy findings. Her proteinuria improved significantly over a 10-month period with angiotensin-converting enzyme inhibitor therapy, lisinopril 40 mg once daily. This case adds to the growing recognition that thin basement membrane nephropathy may not always follow a benign course and highlights the importance of careful evaluation and management when clinical features fall outside the expected pattern. A comprehensive literature review is also provided, summarizing similar presentations and management strategies.
Background and Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease (ESRD). Progressive renal cyst growth in ADPKD can exert mass effects, including compression of the inferior vena cava (IVC), a rare but clinically significant complication with implications for hemodynamic stability and renal outcomes. This study evaluated the prevalence of IVC compression in ADPKD and its impact on progression to ESRD, mortality, and overall survival. We aimed to provide quantitative measures to elucidate its prognostic significance. Materials and Methods: Using the TriNetX database, we conducted a retrospective cohort study of 658 ADPKD patients with IVC compression, comparing them to unmatched controls without compression. Outcomes included ESRD incidence, mortality, and survival. Kaplan–Meier curves and hazard ratios (HRs) with 95% confidence intervals (CIs) were used for analysis. Results: ESRD Risk: IVC compression was associated with a higher risk of ESRD (77.4% vs. 29.7%, RR: 2.61, 95% CI: 2.49–2.73, p < 0.001). Survival Probability: 5-year Survival was significantly reduced in patients with IVC compression (42.6%) compared to controls (61.7%) (HR: 4.00, 95% CI: 3.45–4.63, p = 0.002). Mortality: Mortality was higher in the compression group (29.2% vs. 9.1%). Combined Impact: ESRD patients with IVC compression had a lower survival rate (11.9%) than ESRD patients without compression (28.5%) (HR: 5.60, 95% CI: 5.12–6.13, p < 0.001). Conclusions: IVC compression in ADPKD is associated with significantly worse outcomes, including increased ESRD risk, higher mortality, and reduced survival. These findings underscore the importance of early diagnosis and targeted management strategies.